Tourmaline Bio (TRML) to Release Quarterly Earnings on Thursday

Tourmaline Bio (NASDAQ:TRML) is projected to announce its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of ($0.96) per share for the quarter. Investors can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Thursday, November 13, 2025 at 8:30 AM ET.

Tourmaline Bio (NASDAQ:TRML) last posted its earnings results on Wednesday, August 13th. The company reported ($0.90) EPS for the quarter, beating analysts’ consensus estimates of ($0.94) by $0.04. On average, analysts expect Tourmaline Bio to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Tourmaline Bio Price Performance

NASDAQ:TRML opened at $47.98 on Wednesday. Tourmaline Bio has a 52 week low of $11.56 and a 52 week high of $48.27. The company has a market capitalization of $1.23 billion, a P/E ratio of -13.99 and a beta of 2.27. The stock’s fifty day moving average is $43.71 and its two-hundred day moving average is $27.29.

Institutional Investors Weigh In On Tourmaline Bio

A number of institutional investors have recently modified their holdings of TRML. Creative Planning acquired a new stake in shares of Tourmaline Bio in the second quarter valued at $201,000. American Century Companies Inc. grew its stake in Tourmaline Bio by 12.6% during the 2nd quarter. American Century Companies Inc. now owns 40,564 shares of the company’s stock worth $649,000 after purchasing an additional 4,546 shares in the last quarter. Invesco Ltd. grew its stake in Tourmaline Bio by 28.6% during the 2nd quarter. Invesco Ltd. now owns 25,626 shares of the company’s stock worth $410,000 after purchasing an additional 5,706 shares in the last quarter. Nantahala Capital Management LLC grew its stake in Tourmaline Bio by 4.8% during the 2nd quarter. Nantahala Capital Management LLC now owns 558,187 shares of the company’s stock worth $8,925,000 after purchasing an additional 25,363 shares in the last quarter. Finally, QVT Financial LP grew its stake in Tourmaline Bio by 46.2% during the 2nd quarter. QVT Financial LP now owns 2,154,653 shares of the company’s stock worth $34,453,000 after purchasing an additional 681,284 shares in the last quarter. 91.89% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have commented on TRML shares. Weiss Ratings restated a “sell (d-)” rating on shares of Tourmaline Bio in a research report on Wednesday, October 8th. HC Wainwright downgraded Tourmaline Bio from a “buy” rating to a “neutral” rating and reduced their target price for the company from $50.00 to $48.00 in a research report on Wednesday, September 10th. Lifesci Capital downgraded Tourmaline Bio from an “outperform” rating to a “hold” rating and set a $48.00 target price on the stock. in a research report on Tuesday, September 9th. Chardan Capital downgraded Tourmaline Bio from a “buy” rating to a “neutral” rating and reduced their target price for the company from $70.00 to $48.00 in a research report on Wednesday, September 10th. Finally, Truist Financial cut Tourmaline Bio from a “buy” rating to a “hold” rating and dropped their price objective for the company from $63.00 to $48.00 in a research note on Wednesday, September 10th. One analyst has rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $45.65.

About Tourmaline Bio

Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.